Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The aim of this study is to evaluate the effectiveness of 111In-DTPA-Phe1-octreotide infusions after selective catheterization of the hepatic artery in inoperable metastasised liver, sst2 receptor-positive neuroendocrine tumours due to the effect of 111In Auger electron emission, minimising in parallel the toxicity of non-target tissue.
The average dose per session administered monthly to each patient (17 cases in total) was 6.3 ± 2.3 GBq. Repetitions did not exceed 12-fold, except in one case (15 sessions). Response assessment was classified according to the Response Evaluating Criteria in Solid Tumours. CT/MRI scans were performed as baseline before, during and after the end of treatment, and monthly ultrasound images for follow-up measurements. Toxicity (World Health Organization criteria) was measured using blood and urine tests of renal, hepatic and bone marrow function.
Complete response was achieved in one (5.9%) patient and partial in eight (47.0%), and disease stabilization in 3 (17.7%) patients; five (29.4%) did not respond. A 32-month median survival time was estimated in 12 (70.5%). Nine of these 12 surviving had a mean target diameter shrinkage from 144 ± 81 to 60 ± 59 mm. Grade 1 erythro-, leuko- and thrombo-cytopenia occurred in three (17.6%) cases.
In unresectable metastatic liver lesions positive for somatostatin receptors repeated, transhepatic high doses of 111In-DTPA-Phe1-octreotide show an effective therapeutic outcome. Given the locoregional modality character of the administration technique plus the extremely short range of 111In Auger and internal conversion electrons emission, no nephro-, liver- or myelo-toxicity has so far been observed.
- Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–98. CrossRef
- Janson ET, Westlin J-E, Öhrvall U, Öberg K, Lukinius A. Nuclear localization of 111In after intravenous injections of [111In-DTPA-d-Phe1]-octreotide in patients with neuroendocrine tumors. J Nucl Med. 2000;41:1514–8.
- Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–31. CrossRef
- De Jong M, Bernard BF, De Bruin E, Van Gameren A, Bakker WH, Visser TJ, et al. Internalization of radiolabelled [DTPA°]octreotide and [DOTA°, Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun. 1998;19:283–8. CrossRef
- Anderson P, Forssel-Aronsson E, Johanson V, Wängberg B, Nilsson O, Fjälling M, et al. Internalization of indium-111 into human neuroendocrine tumor cell after incubation with indium-11-DTPA-d-Phe1-octreotide. J Nucl Med. 1996;37:2002–6.
- Bass LA, Lanahan MV, Duncan JR, Erion JL, Srinivasan A, Schmidt MA, et al. Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-d-Phe1-octreotide. Bioconjug Chem. 1998;9:192–200. CrossRef
- Krenning EP, Kooij PPM, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D.Phe1]-octreotide; a case history. Ann NY Acad Sci 1994;733:496–506. CrossRef
- Kaltsas GA, Stefanidou Z, Papadogias D, Grossmann A. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogue octreotide. Hormones. 2002;1(3):149–56.
- Adelstein SJ. The Auger process: a therapeutic promise? AJR. 1993;160:707–13.
- Breeman WA, De Jong M, Kwekkeboom DK, Valkema R, Bakker WH, Kooij PPM, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med. 2001;28:1421–9. CrossRef
- McLean JR, Wilkinson D. The radiation dose to cells in vitro from intracellular indium-111. Biochem Cell Biol. 1989;67:661–5. CrossRef
- Mariani G, Bodei L, Adelstein SJ, Kassis AI, et al. Emerging roles for radiometabolic therapy of tumours based on auger electron emission. J Nucl Med. 2000;41:1519–21.
- Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide. therapy. J Nucl Med. 2005;46:4S–12S.
- Wiseman GA, Kvols LK. The radiolabelled MIBG and Somatostatin analogues. Semin Nucl Med 1995;XXV(3):272–8. CrossRef
- De Jong M, Bakker WH, Krenning EP, Breeman WAP, Van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA, D-Phe1, Tyr3]-octreotide; a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997;24:368–71. CrossRef
- Limouris GS, Lyra M, Skarlos D, Hatziioannou A, Gouliamos A, Moulopoulou A, et al. Auger and conversion electron therapy with In-111 pentetreotide in hepatocellular carcinoma. In: Bergmann H, Koehn H, Sinzinger H, editors. Radioactive isotopes in clinical medicine and research. Boston: Birkhäuser; 1999. p. 551–4.
- Valkema R, De Jong M, Bakker WH, Breeman WAP, Kooij PPM, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [111In-DTPA°]octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32(2):110–22. CrossRef
- Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, De Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA°, Tyr3]octreotate. Eur J Nucl Med. 2003;30:417–22.
- Caplin ME, Mielcarek W, Buscombe JR, Jones AL, Croasdale PL, Cooper MS, et al. Toxicity of high-activity in-111 octreotide therapy in patients with disseminated neuroendocrine tumours. Nucl Med Commun. 2000;21:97–102. CrossRef
- Lafortune M, Madore F, Patriquin H, Breton G. Segmental anatomy of the liver; a US approach to the Couinaud nomenclature. Radiology. 1991;181:443–8.
- Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40:37–61.
- Kontogeorgakos D, Dimitriou P, Limouris GS, Vlachos LJ. Patient specific dosimetry calculations during therapy with in-111-DTPA-d-Phe1-octreotide infusions after catheterization of the hepatic artery using mathematical models of different anatomical sizes. J Nucl Med. 2006;47(9):1476–82.
- Therasse P, Arbuck SG, Eienhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst. 2000;92(30):205–16. CrossRef
- Stabin M. MIRDOSE: the personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538–46.
- Hellman P, Lundström T, Öhrvall V, Eriksson B, Skogseid B, Öberg K, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg. 2002;26:991–97. CrossRef
- Öberg K. Therapeutic alternative in metastasizing neuroendocrine tumours; in carefully selected cases liver transplantation is possible? Laekartidningen. 1999;96:3745–7.
- Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumours; a retrospective single-center analysis. Digestion. 2003;68:94–101. CrossRef
- Dodd GD, Soulen MC, Kane RA, Livraghi T, Lees WR, Yamashita Y, et al. Minimally invasive treatment of malignant hepatic tumours; at the threshold of major breakthrough. Radiographics. 2000;20:9–27.
- Öberg K. Carcinoid tumours: molecular genetics, tumour biology and update of diagnosis and treatment. Curr Opin Oncol. 2002;14:38–45. CrossRef
- Öberg K. Interferon in the management of neuroendocrine GEP-tumours: a review. Digestion 2000;62(Suppl 1):92–7.
- Kaltsas GA, Besser MG, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25(3):458–511. CrossRef
- Kaltsas GA, Mucherjee JJ, Plowman PN, Grassman AB. The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours. Clin Endocrinol. 2001;55:575–87. CrossRef
- Wang DG. Apoptosis in neuroendocrine tumours. Clin Endocrinol. 1999;51:1–9. CrossRef
- Virgolini I, Britton K, Buscome JR, Moncay R, Paganelli G, Riva P. In- and Y-DOTA lanreotide: results and implications of the Mauritius trial. Semin Nucl Med. 2000;32:148–55. CrossRef
- Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with Y-90-d-Phe1-Tyr3-octreotide. Eur J Nucl Med. 2001;28:426–34. CrossRef
- Handkiewicz Junak D, Baum R, Jarzab B. Leukocyte and white blood cell toxicity during long-term peptide receptor radiotherapy using Y-90 and Lu-177 labelled somatostatin analogues. Eur J Nucl Med 2005;32(9):S100.
- Kwekkeboom DJ, Bakker WH, Kooij PPM, Konijnenberg MW, Srinivasan A, Erion JL, et al. Lu-177-DOTA Tyr octreotate: comparison with In-111-DTPA-octreotide in patients. Eur J Nucl Med. 2001;28:1319–25. CrossRef
- Anthony LB, Woltering EA, Espanan GD, Cronin MD, Maloney TJ, McCarthy KE, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32(2):123–32. CrossRef
- Buscombe JR, Caplin ME, Hilson JW. Long-term efficacy of high-activity 111In-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med. 2003;44:1–6.
- Förster GJ, Engelbach M, Brockmann J, Reber H, Buchholz H-G, Mäcke HR, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide. Eur J Nucl Med. 2001;28:1743–50. CrossRef
- Helisch A, Förster GJ, Reber H, Buchholz H-G, Arnold R, Göke B, et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31(10):1386–92. CrossRef
- Goddu SM, Budinger TF. MIRD: cellular S values. Reston, VA: SNM; 1997.
- Buchegger F, Perillo-Adamer F, Dupertuis YM, Bischof Delaloye A. Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging. 2006;33(11):1352–63. CrossRef
- Health Physics J. RADAR; 2008. http://www.doseinfo-radar.com/RADARSoft.html
- Limouris GS, Dimitropoulos N, Kontogeorgakos D, Papanikolos G, Koutoulidis V, Hatzioannou A, et al. Evaluation of the therapeutic response to In-111-DTPA octreotide-based targeted therapy in liver metastatic neuroendocrine tumours according to CT/MRI/US findings. Cancer Biother Radiopharm. 2005;20(2):215–7. CrossRef
- Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nuclear Med. 2005;46(Suppl 1):62–6.
- Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med. 2003;30:207–16.
- Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med. 2002;43(5):610–6.
- Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47(9):1467–75.
- De Jong M, Valkema R, Van Gameren A, Van Boven H, Bex A, Van de Weyer EP, et al. Inhomogenous localization of radioactivity in the human kidney after injection of [111In-DTPA]octreotide. J Nucl Med. 2004;45(7):1168–71.
- Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases
European Journal of Nuclear Medicine and Molecular Imaging
Volume 35, Issue 10 , pp 1827-1837
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Therapeutic infusions
- Hepatic artery catheterization
- Industry Sectors
- Author Affiliations
- 1. Divisions of Nuclear Medicine, Radiology I Department, Aretaieion University Hospital, Athens Medical School, Athens, Greece
- 2. Divisions of Angiography, Radiology I Department, Aretaieion University Hospital, Athens Medical School, Athens, Greece